These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11434941)

  • 1. No Influence of acute hypertriglyceridemia on plasma t-PA in healthy male volunteers.
    Kemme MJ; Burggraaf J; Schoemaker RC; Cohen AF
    Thromb Res; 2001 Jul; 103(1):9-16. PubMed ID: 11434941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator.
    van Griensven JM; Huisman LG; Stuurman T; Dooijewaard G; Kroon R; Schoemaker RC; Kluft K; Cohen AF
    Clin Pharmacol Ther; 1996 Nov; 60(5):504-11. PubMed ID: 8941023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction study between nifedipine and recombinant tissue-type plasminogen activator in healthy subjects.
    De Boer A; Kluft C; Kasper FJ; Kroon JM; Schoemaker HC; Breimer DD; Soons PA; Cohen AF
    Br J Clin Pharmacol; 1993 Aug; 36(2):99-104. PubMed ID: 8398589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of submaximal exercise on fibrinolysis.
    Fras Z; Keber D; Chandler WL
    Blood Coagul Fibrinolysis; 2004 Apr; 15(3):227-34. PubMed ID: 15060418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
    Lucore CL; Fujii S; Sobel BE
    Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator.
    de Boer A; Kluft C; Kroon JM; Kasper FJ; Schoemaker HC; Pruis J; Breimer DD; Soons PA; Emeis JJ; Cohen AF
    Thromb Haemost; 1992 Jan; 67(1):83-7. PubMed ID: 1615490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
    Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction.
    Koster RW; Cohen AF; Kluft C; Kasper FJ; van der Wouw PA; Weatherley BC
    Clin Pharmacol Ther; 1991 Sep; 50(3):267-77. PubMed ID: 1914361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise.
    de Boer A; Kluft C; Dooijewaard G; Kasper FJ; Kroon JM; Breimer DD; Stiekema JC; Cohen AF
    Thromb Haemost; 1992 Nov; 68(5):550-5. PubMed ID: 1280862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.
    Leiper K; Croll A; Booth NA; Moore NR; Sinclair T; Bennett B
    J Clin Pathol; 1994 Mar; 47(3):214-7. PubMed ID: 8163691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men.
    Chia S; Ludlam CA; Fox KA; Newby DE
    J Am Coll Cardiol; 2003 Jan; 41(2):333-9. PubMed ID: 12535831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids.
    Petersen KR; Kjems LL; Skouby SO; Andersen LF; Jespersen J
    Metabolism; 1996 Jul; 45(7):833-7. PubMed ID: 8692017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
    van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
    Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splanchnic extraction and clearance of tissue plasminogen activator (t-PA) after injection of recombinant t-PA (Actilyse) in resting healthy subjects is proportional to the arterial concentration.
    Jørgensen M; Tønnesen KH; Petersen KR; Jespersen J; Gram J; Vinberg N
    Blood Coagul Fibrinolysis; 2002 Jun; 13(4):331-8. PubMed ID: 12032399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
    Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE
    Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.
    Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS
    Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis.
    Huber K; Kirchheimer JC; Korninger C; Binder BR
    Thromb Res; 1991 Jun; 62(5):491-500. PubMed ID: 1910213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
    Chen LY; Nichols WW; Saldeen TG; Mehta JL
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers.
    Seifried E; Tanswell P; Rijken DC; Barrett-Bergshoeff MM; Su CA; Kluft C
    Arzneimittelforschung; 1988 Mar; 38(3):418-22. PubMed ID: 3132929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.